Clinical Trials
15 trialsNCT06583395 2024-11-01
QUANTUM
VitaMed Research LLC
Enrolling by invitation
NCT05181826 2024-06-14
ELITE
Helio Genomics
Unknown
NCT05635266 2024-05-07
Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives
Sanguine Biosciences
Unknown
NCT01931644 2024-04-18
At-Home Research Study for Patients With Autoimmune, Inflammatory, Genetic, Hematological, Infectious, Neurological, CNS, Oncological, Respiratory, Metabolic Conditions
Sanguine Biosciences
Completed
NCT01511393 2023-06-13
An Active Surveillance Program for Cases of Medullary Thyroid Carcinoma (MTC)
Novo Nordisk A/S
Enrolling by invitation
NCT02073474 2022-12-20
An Observational Post-Marketing Safety Registry of Sativex®
Jazz Pharmaceuticals
Completed
NCT01637935 2018-03-07
Cohort Study of Pioglitazone and Bladder Cancer in Patients With Type II Diabetes
Takeda
Completed
NCT02958956 2018-03-07
Cohort Study of Pioglitazone and Cancer Incidence in Participants With Diabetes Mellitus.
Takeda
Completed
NCT02958995 2018-03-07
Epidemiologic Study Of Diabetes And Cancer Risk
Takeda
Completed
NCT01236053 2017-07-06
Cancer in Patients With Gabapentin (GPRD)
GlaxoSmithKline
Completed
NCT01138124 2017-05-30
Gabapentin and Risk of Pancreatic Cancer and Renal Cancer (GPRD)
GlaxoSmithKline
Completed
NCT00518102 2016-07-19
The Risk of Cancer in Users of Regranex (Becaplermin) and Matched Comparators (Nonusers of Regranex [Becaplermin])
Ethicon, Inc.
Completed
NCT01235260 2016-07-19
Becaplermin Use and Cancer Risk in a Patient Population of U.S. Veterans With Diabetes
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Completed
NCT02608853 2015-11-20
Estimation of Malignancy Rates Within Humedica Patient Populations Sampled to be Representative of Liraglutide Initiators and LEADERâ„¢ Trial Participants
Novo Nordisk A/S
Completed
NCT01284608 2012-12-24
UROCOR
AstraZeneca
Completed